These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29663572)

  • 1. A review of studies evaluating the effectiveness of risk minimisation measures in Europe using the European Union electronic Register of Post-Authorization Studies.
    Vora P; Artime E; Soriano-Gabarró M; Qizilbash N; Singh V; Asiimwe A
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):695-706. PubMed ID: 29663572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study design, process and outcome indicators of post-authorization studies aimed at evaluating the effectiveness of risk minimization measures in the EU PAS Register.
    Farcas A; Huruba M; Mogosan C
    Br J Clin Pharmacol; 2019 Mar; 85(3):476-491. PubMed ID: 30497102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in Europe.
    Jouaville LS; Paul T; Almas MF
    Pharmacoepidemiol Drug Saf; 2021 Sep; 30(9):1143-1152. PubMed ID: 34092001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are risk minimization measures for approved drugs in Europe effective? A systematic review.
    Artime E; Qizilbash N; Garrido-Estepa M; Vora P; Soriano-Gabarró M; Asiimwe A; Pocock S
    Expert Opin Drug Saf; 2019 May; 18(5):443-454. PubMed ID: 31032651
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk Minimisation Evaluation with Process Indicators and Behavioural or Health Outcomes in Europe: Systematic Review.
    Artime E; Qizilbash N; Herruzo R; Garrido-Estepa M
    Pharmaceut Med; 2020 Dec; 34(6):387-400. PubMed ID: 33141411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of risk minimisation measures for valproate: A drug utilisation study in Europe.
    Toussi M; Shlaen M; Coste F; de Voogd H; Dimos V; Kaplan S
    Pharmacoepidemiol Drug Saf; 2021 Mar; 30(3):292-303. PubMed ID: 33108674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study Design and Evaluation of Risk Minimization Measures: A Review of Studies Submitted to the European Medicines Agency for Cardiovascular, Endocrinology, and Metabolic Drugs.
    Mazzaglia G; Straus SMJ; Arlett P; da Silva D; Janssen H; Raine J; Alteri E
    Drug Saf; 2018 Feb; 41(2):191-202. PubMed ID: 29124666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study.
    Abtahi S; Pajouheshnia R; Durán CE; Riera-Arnau J; Gamba M; Alsina E; Hoxhaj V; Andersen M; Bartolini C; Kristiansen SB; Brown J; Hallgreen CE; Garcia-Poza P; Gardarsdottir H; Gini R; Girardi A; Holthuis E; Huerta C; Ibánez L; Limoncella G; Martín-Pérez M; Paoletti O; Roberto G; Souverein P; Swart KMA; Wing K; Sturkenboom M; Klungel O
    Drug Saf; 2023 Jul; 46(7):689-702. PubMed ID: 37294532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight.
    Engel P; Almas MF; De Bruin ML; Starzyk K; Blackburn S; Dreyer NA
    Br J Clin Pharmacol; 2017 Apr; 83(4):884-893. PubMed ID: 27780289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of Studies Evaluating Effectiveness of Risk Minimization Measures Assessed by the European Medicines Agency Between 2016 and 2021.
    Grupstra RJ; Goedecke T; Scheffers J; Strassmann V; Gardarsdottir H
    Clin Pharmacol Ther; 2023 Dec; 114(6):1285-1292. PubMed ID: 37634124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional Risk Minimisation Measures for Medicinal Products in the European Union: A Review of the Implementation and Effectiveness of Measures in the United Kingdom by One Marketing Authorisation Holder.
    Agyemang E; Bailey L; Talbot J
    Pharmaceut Med; 2017; 31(2):101-112. PubMed ID: 28413313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk management measures for chemicals in consumer products: documentation, assessment, and communication across the supply chain.
    Bruinen de Bruin Y; Hakkinen PB; Lahaniatis M; Papameletiou D; Del Pozo C; Reina V; Van Engelen J; Heinemeyer G; Viso AC; Rodriguez C; Jantunen M
    J Expo Sci Environ Epidemiol; 2007 Dec; 17 Suppl 1():S55-66. PubMed ID: 17609687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A descriptive review of additional risk minimisation measures applied to EU centrally authorised medicines 2006-2015.
    Rubino A; Artime E
    Expert Opin Drug Saf; 2017 Aug; 16(8):877-884. PubMed ID: 28548608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of the European post-authorisation study register post-authorization studies performed in Europe from September 2010 to December 2018.
    Sultana J; Crisafulli S; Almas M; Antonazzo IC; Baan E; Bartolini C; Bertuccio MP; Bonifazi F; Capuano A; Didio A; Ehrenstein V; Felisi M; Ferrajolo C; Fontana A; Francisca R; Fourrier-Reglat A; Fortuny J; Gini R; Hyeraci G; Hoeve C; Kontogiorgis C; Isgrò V; Lalagkas PN; L'Abbate L; Layton D; Landi A; Narduzzi S; Roque Pereira L; Poulentzas G; Rafaniello C; Roberto G; Scondotto G; Sportiello L; Toma M; Toussi M; Verhamme K; Volpe E; Trifirò G;
    Pharmacoepidemiol Drug Saf; 2022 Jun; 31(6):689-705. PubMed ID: 35092329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ivabradine drug utilization study in five European countries: A multinational, retrospective, observational study to assess effectiveness of risk-minimization measures.
    Salem L; Malouvier A; Blatchford J; Rivero-Ferrer E; Deltour N; Jacquot E
    Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1470-1479. PubMed ID: 31486198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A description of medicines-related safety issues evaluated through a referral procedure at the EU level after 2012.
    Farcas A; Balcescu T; Anghel L; Bucsa C; Mogoșan C
    Expert Opin Drug Saf; 2020 Jun; 19(6):755-762. PubMed ID: 32186202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Description of the Risk Management of Medication Errors for Centrally Authorised Products in the European Union.
    Hoeve CE; Francisca RDC; Zomerdijk I; Sturkenboom MCJM; Straus SMJM
    Drug Saf; 2020 Jan; 43(1):45-55. PubMed ID: 31617081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interest of pharmacoepidemiology in pharmacovigilance: Post-authorization safety studies in regulatory pharmacovigilance activity.
    Abou Taam M; Ferard C; Rocle P; Maison P
    Therapie; 2019 Apr; 74(2):301-306. PubMed ID: 30704766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.